10,927 Shares in Bioventus Inc. $BVS Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. acquired a new stake in Bioventus Inc. (NYSE:BVS) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,927 shares of the company’s stock, valued at approximately $72,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Bioventus by 7.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after purchasing an additional 1,538 shares during the last quarter. EntryPoint Capital LLC lifted its position in Bioventus by 7.8% during the first quarter. EntryPoint Capital LLC now owns 28,371 shares of the company’s stock worth $260,000 after acquiring an additional 2,048 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of Bioventus by 12.0% during the second quarter. Harbor Capital Advisors Inc. now owns 24,482 shares of the company’s stock worth $162,000 after acquiring an additional 2,615 shares during the period. EP Wealth Advisors LLC grew its position in shares of Bioventus by 24.1% in the first quarter. EP Wealth Advisors LLC now owns 17,490 shares of the company’s stock valued at $160,000 after purchasing an additional 3,394 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Bioventus by 35.6% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,181 shares of the company’s stock worth $157,000 after buying an additional 4,513 shares during the period. 62.94% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Michelle Mcmurry-Heath sold 17,701 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $7.42, for a total transaction of $131,341.42. Following the transaction, the director directly owned 56,997 shares of the company’s stock, valued at approximately $422,917.74. This trade represents a 23.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 33.00% of the stock is currently owned by insiders.

Bioventus Trading Down 2.9%

BVS stock opened at $7.35 on Friday. Bioventus Inc. has a 52 week low of $5.81 and a 52 week high of $12.61. The company has a market capitalization of $607.69 million, a PE ratio of -12.05 and a beta of 0.80. The company’s 50-day simple moving average is $6.98 and its 200 day simple moving average is $6.88. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.